Hybrid adeno-retroviral vector for the transfection of cells

US7052904B2 · kind B2 · utility

Assignee

• The United States of America as Represented by the Secretary of the Department of Health and Human Services · US

Inventors

• Changyu Zheng · Rockville, US
• Brian O'Connell · Dublin, IE
• Bruce Baum · Bethesda, US

Key dates

• Filing date: Jan 30, 2001
• Grant date: May 30, 2006
• Expiry date: May 14, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2830/60
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

An adenovirus, including adenoviral capsid proteins, and a replication-defective adenoviral vector that includes a 5′ retroviral LTR nucleic acid sequence, a 3′ retroviral LTR nucleic acid sequence, a nucleic acid sequence encoding a portion of a retroviral envelope protein adjacent to either the 5′ LTR or the 3′ LTR nucleic acid sequence, a retroviral packaging sequence and a nucleic acid sequence encoding a transgene located between the 5′ LTR and the 3′ LTR is provided. Host cells infected with this adenovirus are also provided. An adenoviral vector is provided that includes an adenoviral polynucleotide sequence comprising a nucleic acid encoding a transgene, a retroviral packaging signal, a 5′ and a 3′ retroviral LTR, and a portion of a retroviral envelope polypeptide, wherein the adenoviral polynucleotide sequence does not encode one or more of E1, E3 or E4. A method for transforming a cell is also provided using a virus or a vector of the invention, as is a method for introducing a transgene into a cell that is not able to produce viral particles with a single viral vector. A method is also provided for preventing or treating disorder in a subject using the adenoviral vectors…